Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2000 October;41(5) > The Journal of Cardiovascular Surgery 2000 October;41(5):773-6

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE JOURNAL OF CARDIOVASCULAR SURGERY

Rivista di Chirurgia Cardiaca, Vascolare e Toracica


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632


eTOC

 

CASE REPORTS  THORACIC PAPERS


The Journal of Cardiovascular Surgery 2000 October;41(5):773-6

lingua: Inglese

Long-term survival of patients treated with octreotide for metastatic well differentiated neuroendocrine carcinoma of the lung

Filosso P. L., Croce S. *, Oliaro A., Ruffini E.

From the Department of Thoracic Surgery *Department of Biomedical Sciences and Human Oncology University of Turin, Turin, Italy


PDF  


Two ­patients ­with a rad­i­cal­ly oper­at­ed ­well dif­fer­en­tiat­ed neu­ro­en­do­crine car­ci­no­ma (­WDNC) of the ­lung who devel­oped a car­ci­noid syn­drome due to met­a­stat­ic ­spread of the ­tumor are report­ed. Treatment ­with som­a­tos­ta­tin ana­logue octre­o­tide was admin­is­tered to ­both ­patients fol­low­ing ­their refu­sal of a stan­dard chem­o­the­rap­ic reg­i­men. Prompt res­o­lu­tion of the car­ci­noid syn­drome was ­observed in ­both fol­low­ing octre­o­tide treat­ment and ­both ­patients are ­alive and ­well ­after ­more ­than four ­years with­out evi­dence of fur­ther pro­gres­sion of the ­tumor. It is sug­gest­ed ­that oc­tre­o­tide ­should be con­sid­ered as an effec­tive ther­a­py in ­WDNC for the con­trol of the dis­ease and asso­ciat­ed par­a­neo­plas­tic syn­dromes.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail